Celularity

Celularity(CELUW)

FLORHAM PARK, NJ
Biotechnology
WebsiteLinkedInCareers Page

Focus: Placenta-derived stem cells

Celularity is a life sciences company focused on Placenta-derived stem cells.

Cell Therapy
Funding Stage
PUBLIC
Open Jobs
1

Pipeline & Clinical Trials

Phase 1
Clinical Trials (1)
NCT01859117Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU
Phase 1
Phase 1
Clinical Trials (1)
NCT01769755A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
Phase 1
Phase 1
Clinical Trials (1)
NCT04309084Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Phase 1
Phase 1
Clinical Trials (1)
NCT02781467A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Phase 1
CYNK-001
Leukemia
Phase 1
Clinical Trials (1)
NCT04310592Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Phase 1
Phase 1
Clinical Trials (1)
NCT01440192Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis
Phase 1
Phase 1
Clinical Trials (1)
NCT02955550A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
Phase 1
Phase 1
Clinical Trials (1)
NCT04489420Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Phase 1
CYNK-001 systemic and Intra cavity administration
Astrocytoma, Grade IV
Phase 1/2
Clinical Trials (1)
NCT05218408CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05207722CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Phase 1/2
CYNK-001
Coronavirus
Phase 1/2
Clinical Trials (1)
NCT04365101Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Phase 1/2
Phase 2
Clinical Trials (1)
NCT02264288Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease
Phase 2
Human Placenta-Derived Cells PDA001-
Stroke, Acute
Phase 2
Clinical Trials (1)
NCT01310114Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke
Phase 2
Human Placenta-Derived Cells PDA001 Intravenous Infusion
Crohn's Disease
Phase 2
Clinical Trials (1)
NCT01155362A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Phase 2
Phase 2
Clinical Trials (1)
NCT02552277A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy
Phase 2
Phase 2
Clinical Trials (1)
NCT01261403Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis
Phase 2
Phase 2
Clinical Trials (1)
NCT02460081Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
Phase 2

Open Jobs (1)

Operator, Tissue Manufacturing

Florham Park, NJ
Manufacturing
Yesterday
Interview Prep Quick Facts
Portfolio: 17 clinical trials
SEC Filings: 2 available
Open Roles: 1 active job

Financials (FY2024)

Revenue
$23M27%
R&D Spend
$30M(134%)61%
Net Income
-$196M
Cash
$227K
Source: SEC 10-K Filing

Hiring Trend

Stable
1
Open Roles
+1
Added
-1
Filled/Removed

Based on last 4 crawl cycles